These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33246263)

  • 1. Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
    Colafigli G; Scalzulli E; Di Prima A; Pepe S; Loglisci MG; Diverio D; Martelli M; Foà R; Breccia M
    Crit Rev Oncol Hematol; 2021 Jan; 157():103163. PubMed ID: 33246263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
    Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
    Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
    Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
    Goh HG; Lin M; Fukushima T; Saglio G; Kim D; Choi SY; Kim SH; Lee J; Lee YS; Oh SM; Kim DW
    Leuk Lymphoma; 2011 May; 52(5):896-904. PubMed ID: 21338281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
    Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
    J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.
    Alikian M; Ellery P; Forbes M; Gerrard G; Kasperaviciute D; Sosinsky A; Mueller M; Whale AS; Milojkovic D; Apperley J; Huggett JF; Foroni L; Reid AG
    J Mol Diagn; 2016 Mar; 18(2):176-89. PubMed ID: 26857065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients.
    Breccia M; Scalzulli E; Pepe S; Colafigli G; Bisegna ML; Capriata M; Martelli M
    Expert Rev Hematol; 2022 Jan; 15(1):25-32. PubMed ID: 34894984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
    Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
    Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-free remission in chronic myeloid leukemia.
    Molica M; Naqvi K; Cortes JE; Paul S; Kadia TM; Breccia M; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2019 Dec; 17(12):686-696. PubMed ID: 31851157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.
    Chung HJ; Hur M; Yoon S; Hwang K; Lim HS; Kim H; Moon HW; Yun YM
    Ann Lab Med; 2020 Jan; 40(1):72-75. PubMed ID: 31432643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal Residual Disease Eradication in CML: Does It Really Matter?
    Tantravahi SK; Guthula RS; O'Hare T; Deininger MW
    Curr Hematol Malig Rep; 2017 Oct; 12(5):495-505. PubMed ID: 28852963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized Digital Droplet PCR for BCR-ABL.
    Maier J; Lange T; Cross M; Wildenberger K; Niederwieser D; Franke GN
    J Mol Diagn; 2019 Jan; 21(1):27-37. PubMed ID: 30347270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of treatment-free remission in CML, based on molecular monitoring.
    Zhang Z; Zhou X; Zhou X; Cheng Z; Hu Y
    Cancer Med; 2024 Jan; 13(1):e6849. PubMed ID: 38133525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.